Hey there, Alex Haahr Gouliaev

Nordic Life Science asked the CEO of Nuevolution about the offer from Amgen to buy Nuevolution for $166.8 million. Nuevolution’s pipeline and selective deal-making approach has recently proven to be both solid and successful, with presentations of progress in multiple projects, and last week, Amgen made an offer. What’s your comment about the Amgen offer? “The … Continue reading Hey there, Alex Haahr Gouliaev